Viveve Medical (VIVE) Downgraded to “Strong Sell” at ValuEngine

ValuEngine downgraded shares of Viveve Medical (NASDAQ:VIVE) from a sell rating to a strong sell rating in a report issued on Friday morning.

Several other research firms have also issued reports on VIVE. Maxim Group restated a buy rating and set a $11.00 price target on shares of Viveve Medical in a report on Friday, August 11th. Cowen set a $11.00 price target on shares of Viveve Medical and gave the stock a buy rating in a report on Monday, October 23rd. Finally, Mizuho assumed coverage on shares of Viveve Medical in a report on Thursday, November 16th. They set a buy rating and a $10.00 price target for the company. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $10.40.

Viveve Medical (NASDAQ VIVE) opened at $4.95 on Friday. The company has a debt-to-equity ratio of 2.72, a current ratio of 3.89 and a quick ratio of 3.63. Viveve Medical has a fifty-two week low of $3.75 and a fifty-two week high of $11.16.

Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.08). Viveve Medical had a negative return on equity of 275.77% and a negative net margin of 257.58%. The firm had revenue of $4.07 million for the quarter, compared to the consensus estimate of $4.10 million. During the same quarter in the previous year, the business posted ($0.46) EPS. The firm’s revenue for the quarter was up 120.1% compared to the same quarter last year. analysts forecast that Viveve Medical will post -2.04 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in VIVE. Schwab Charles Investment Management Inc. acquired a new stake in shares of Viveve Medical during the 2nd quarter worth approximately $189,000. Rhumbline Advisers acquired a new stake in shares of Viveve Medical during the 2nd quarter worth approximately $110,000. Bank of New York Mellon Corp acquired a new stake in shares of Viveve Medical during the 2nd quarter worth approximately $310,000. JPMorgan Chase & Co. acquired a new stake in shares of Viveve Medical during the 2nd quarter worth approximately $151,000. Finally, Teachers Advisors LLC acquired a new stake in shares of Viveve Medical during the 2nd quarter worth approximately $196,000. 67.02% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://sportsperspectives.com/2017/12/05/viveve-medical-vive-downgraded-to-strong-sell-at-valuengine.html.

Viveve Medical Company Profile

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply